Aurobindo Pharma Limited has informed the Exchange that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company Secures Health Canada NOC for Bevqolva Bevacizumab Biosimilar
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received Notice of Compliance (NOC) from Health Canada for Bevqolva™, its bevacizumab biosimilar. This grants formal marketing authorization after regulatory review confirmed safety, efficacy, and quality standards comparable to the reference drug Avastin (Roche/Genentech). Bevacizumab is a monoclonal antibody used to treat multiple cancers including colorectal and lung cancer, available in 100mg and 400mg formulations. The product was already approved by the UK MHRA and commercially launched there in 2025. Additional regulatory reviews are underway with the European Medicines Agency and Health Canada for two more biosimilar applications.
This regulatory approval strengthens Aurobindo's biologics portfolio and opens the Canadian market for its biosimilar. It demonstrates the company's capability in complex biologic drug development, which could support future revenue growth from international markets.